James Kihara sold $19k of ACAD
PRINCIPAL ACCOUNTING OFFICER at ACADIA PHARMACEUTICALS INC. 1,327 shares at an average of $14.60, traded May 2, 2025, filed May 2, 2025.
Score components
- +15RoleOfficer
- 0Trade size$19k at market
- 0Share of holdings soldSold 5.3% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-011875, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2025 | MOption exercise Common Stock | +2,596 | - | - | 24,853 | May 2, 2025 |
| May 2, 2025 | SOpen-market sale Common Stock10b5-1 | -1,327 | $14.60 | $19k | 23,526 | May 2, 2025 |
| May 1, 2025 | MOption exercise Restricted Stock Unitsderivative | -2,596 | $0.00 | $0 | 5,192 | May 2, 2025 |
Related signals
Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 39Weak | ACADsell ACADIA PHARMACEUTICALS INC | Laura Brege director | $315k 14,446 shares | -49% | |
| 17Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $50k 2,000 shares | -3% | |
| 17Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $90k 4,000 shares | -16% | |
| 2Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $51k 3,498 shares | -5% | |
| 0Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $15k 1,028 shares | -4% | |
| 1Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $40k 2,708 shares | -4% | |
| 2Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $54k 3,171 shares | -5% | |
| 0Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $19k 1,095 shares | -5% | |
| 44Moderate | ACADIA PHARMACEUTICALS INC | Elizabeth A. Garofalo director | $90k 4,919 shares | -22% | |
| 2Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $15k 773 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.